Compare CENTA & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CENTA | ANIP |
|---|---|---|
| Founded | 1955 | 2001 |
| Country | United States | United States |
| Employees | 6000 | N/A |
| Industry | Consumer Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.8B |
| IPO Year | N/A | 1999 |
| Metric | CENTA | ANIP |
|---|---|---|
| Price | $33.87 | $78.51 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $36.75 | ★ $110.00 |
| AVG Volume (30 Days) | 229.9K | ★ 294.9K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 419.23 |
| EPS | N/A | ★ 3.32 |
| Revenue | N/A | ★ $206,547,000.00 |
| Revenue This Year | $1.60 | $21.01 |
| Revenue Next Year | $2.04 | $17.59 |
| P/E Ratio | ★ $13.52 | $23.94 |
| Revenue Growth | N/A | ★ 2.47 |
| 52 Week Low | $25.97 | $56.71 |
| 52 Week High | $37.35 | $99.50 |
| Indicator | CENTA | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 54.40 | 53.02 |
| Support Level | $31.16 | $78.80 |
| Resistance Level | $35.12 | $83.58 |
| Average True Range (ATR) | 0.84 | 2.41 |
| MACD | 0.04 | -0.04 |
| Stochastic Oscillator | 50.75 | 46.30 |
Central Garden & Pet Co offers solutions that support healthier pets, greener lawns, and thriving gardens. Its products include dog and cat treats, chews, toys, beds, containment, grooming supplies, aquatics, small animal and bird supplies, equine and livestock products, insect control solutions, grass seed, wild bird feed, fertilizers, pest controls, live plants, and packet seeds, sold under brands such as Aqueon, Nylabone, Kaytee, Farnam, Pennington, Ferry Morse, Amdro, and Sevin. The company operates through two segments, Pet and Garden, and sells through retailers, independent stores, eCommerce channels, and professional markets. It has sales and distribution operations mainly across the United States, with additional facilities in Canada and Mexico.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.